Showing 1 - 10 of 85
This paper studies oligopolistic competition in off-patent pharmaceutical markets using a vertical product differentiation model. This model can explain the observation that countries with stronger regulations have smaller generic market shares. It can also explain the differences in observed...
Persistent link: https://www.econbiz.de/10005827428
This paper studies oligopolistic competition in off-patent pharmaceutical markets using a vertical product differentiation model. This model can explain the observation that countries with stronger regulations have smaller generic market shares. It can also explain the differences in observed...
Persistent link: https://www.econbiz.de/10005772420
This paper provides empirical evidence on the explanatory factors affecting introductory prices of new pharmaceuticals …
Persistent link: https://www.econbiz.de/10010553343
This paper studies price determination in pharmaceutical markets using data for 25 countries, six years and a comprehensive list of products from the MIDAS IMS database. We show that market power and the quality of the product has a significantly positive impact of prices. The nationality of the...
Persistent link: https://www.econbiz.de/10005772557
We analyze the effect of multimarket contact on the pricing behavior of pharmaceutical firms controlling for different levels of regulatory constraints using the IMS MIDAS database for the industry. Theoretically, under product differentiation, firms may find it profitable to allocate their...
Persistent link: https://www.econbiz.de/10005772572
Broadly speaking, pharmaceutical policy in Spain has been unable to control either the price or the volume of drugs prescribed. Limited attempts have been made to bring together the regulation of the pharmaceutical market and policies, in pursuit of the desired goals of efficiency and quality....
Persistent link: https://www.econbiz.de/10005704844
Broadly speaking, pharmaceutical policy in Spain has been unable to control either the price or the volume of drugs prescribed. Limited attempts have been made to bring together the regulation of the pharmaceutical market and policies, in pursuit of the desired goals of efficiency and quality....
Persistent link: https://www.econbiz.de/10005707999
The organisation of inpatient care provision has undergone significant reform in many southern European countries. Overall across Europe, public management is moving towards the introduction of more flexibility and autonomy . In this setting, the promotion of the further decentralisation of...
Persistent link: https://www.econbiz.de/10005827530
We apply a multilevel hierarchical model to explore whether an aggregation fallacy exists in estimating the income elasticity of health expenditure by ignoring the regional composition of national health expenditure figures. We use data for 110 regions in eight OECD countries in 1997: Australia,...
Persistent link: https://www.econbiz.de/10005771924
effects on choice of appropriate pharmaceuticals, insurer savings, total drug expenditures, prices of referenced and non …) if cost inflation in pharmaceuticals is due to high prices rather than to the excess of prescription rates, (2) when the …
Persistent link: https://www.econbiz.de/10005771933